Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Xavier Castellsagué; Kevin A Ault; F Xavier Bosch; Darron R Brown; Jack Cuzick; Daron G Ferris; Elmar A Joura; Suzanne M Garland; Anna R. Giuliano; Mauricio Hernandez-Avila; Warner Huh; Ole-Erik Iversen; Susanne K. Kjaer; Joaquin Luna; Joseph Monsonego; Nubia Muñoz; Evan R Myers; Jorma Paavonen; Punnee Pitisuttihum; Marc Steben; Cosette M Wheeler; Gonzalo Perez; Alfred Saah; Alain Luxembourg; Heather L Sings; Christine Velicer

doi:10.1016/j.pvr.2016.03.002

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Xavier Castellsagué^*, Kevin A Ault, F Xavier Bosch, Darron R Brown, Jack Cuzick, Daron G Ferris, Elmar A Joura, Suzanne M Garland, Anna R. Giuliano, Mauricio Hernandez-Avila, Warner Huh, Ole-Erik Iversen, Susanne K. Kjaer, Joaquin Luna, Joseph Monsonego, Nubia Muñoz, Evan R Myers, Jorma Paavonen, Punnee Pitisuttihum, Marc StebenCosette M Wheeler, Gonzalo Perez, Alfred Saah, Alain Luxembourg, Heather L Sings, Christine Velicer

^*Corresponding author for this work

Department of Clinical Medicine

20 Citations (Scopus)

Abstract

Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

Original language	English
Journal	Papillomavirus Research
Volume	2
Pages (from-to)	61-69
Number of pages	9
DOIs	https://doi.org/10.1016/j.pvr.2016.03.002
Publication status	Published - 2016

Keywords

Adenocarcinoma in situ
Cervical cancer
Cervical intraepithelial neoplasia
Human papillomavirus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pvr.2016.03.002Licence: CC BY-NC-ND

Cite this

Castellsagué, X., Ault, K. A., Bosch, F. X., Brown, D. R., Cuzick, J., Ferris, D. G., Joura, E. A., Garland, S. M., Giuliano, A. R., Hernandez-Avila, M., Huh, W., Iversen, O.-E., Kjaer, S. K., Luna, J., Monsonego, J., Muñoz, N., Myers, E. R., Paavonen, J., Pitisuttihum, P., ... Velicer, C. (2016). Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research, 2, 61-69. https://doi.org/10.1016/j.pvr.2016.03.002

Castellsagué, X, Ault, KA, Bosch, FX, Brown, DR, Cuzick, J, Ferris, DG, Joura, EA, Garland, SM, Giuliano, AR, Hernandez-Avila, M, Huh, W, Iversen, O-E, Kjaer, SK, Luna, J, Monsonego, J, Muñoz, N, Myers, ER, Paavonen, J, Pitisuttihum, P, Steben, M, Wheeler, CM, Perez, G, Saah, A, Luxembourg, A, Sings, HL & Velicer, C 2016, 'Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region', Papillomavirus Research, vol. 2, pp. 61-69. https://doi.org/10.1016/j.pvr.2016.03.002

@article{56285e83763343ebb841479f2609e1b3,

title = "Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region",

abstract = "Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.",

keywords = "Adenocarcinoma in situ, Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus",

author = "Xavier Castellsagu{\'e} and Ault, {Kevin A} and Bosch, {F Xavier} and Brown, {Darron R} and Jack Cuzick and Ferris, {Daron G} and Joura, {Elmar A} and Garland, {Suzanne M} and Giuliano, {Anna R.} and Mauricio Hernandez-Avila and Warner Huh and Ole-Erik Iversen and Kjaer, {Susanne K.} and Joaquin Luna and Joseph Monsonego and Nubia Mu{\~n}oz and Myers, {Evan R} and Jorma Paavonen and Punnee Pitisuttihum and Marc Steben and Wheeler, {Cosette M} and Gonzalo Perez and Alfred Saah and Alain Luxembourg and Sings, {Heather L} and Christine Velicer",

year = "2016",

doi = "10.1016/j.pvr.2016.03.002",

language = "English",

volume = "2",

pages = "61--69",

journal = "Papillomavirus Research",

issn = "2405-8521",

publisher = "Elsevier",

}

TY - JOUR

T1 - Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

AU - Castellsagué, Xavier

AU - Ault, Kevin A

AU - Bosch, F Xavier

AU - Brown, Darron R

AU - Cuzick, Jack

AU - Ferris, Daron G

AU - Joura, Elmar A

AU - Garland, Suzanne M

AU - Giuliano, Anna R.

AU - Hernandez-Avila, Mauricio

AU - Huh, Warner

AU - Iversen, Ole-Erik

AU - Kjaer, Susanne K.

AU - Luna, Joaquin

AU - Monsonego, Joseph

AU - Muñoz, Nubia

AU - Myers, Evan R

AU - Paavonen, Jorma

AU - Pitisuttihum, Punnee

AU - Steben, Marc

AU - Wheeler, Cosette M

AU - Perez, Gonzalo

AU - Saah, Alfred

AU - Luxembourg, Alain

AU - Sings, Heather L

AU - Velicer, Christine

PY - 2016

Y1 - 2016

N2 - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

AB - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

KW - Adenocarcinoma in situ

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - Human papillomavirus

U2 - 10.1016/j.pvr.2016.03.002

DO - 10.1016/j.pvr.2016.03.002

M3 - Journal article

C2 - 29074187

AN - SCOPUS:84961675401

SN - 2405-8521

VL - 2

SP - 61

EP - 69

JO - Papillomavirus Research

JF - Papillomavirus Research

ER -

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this